Design of the MC38-hPD‑L1-LZ cell line

We generated the MC38-hPD-L1-LZ clonal cell line expressing high levels of human PD-L1 and forming solid tumors in vivo. An optimized version of a luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

‍

MC38-hPD-L1-LZ features

  • Form solid tumors upon subcutaneous injection in fully immunocompetent mice
  • hPD-L1 is entirely humanized
  • Express a luciferase-ZsGreen (LZ) fusion reporter
  • Injected cells can be followed in vivo and ex vivo with our LZ reporter

Validation

Related ressources et publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Discover related products to

MC38-hPD-L1-LZ

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mouse
ICP
PD-1
GITR
ICP (multi-target)

hPD-1/hGITR/hGITRL

The hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice. in vivo imaging and ex vivo tracking.

Mouse
ICP
PD-1
PD-L1
ICP (multi-target)

hPD-1/hPD-L1

The hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice. in vivo imaging and ex vivo tracking.

Mouse
ICP
PD-1
Lag3
ICP (multi-target)

hPD-1/hLAG3

The hPD-1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice. in vivo imaging and ex vivo tracking.

Mouse
ICP
PD-1
VISTA
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice. in vivo imaging and ex vivo tracking.

Mouse
ICP
PD-1
TIM3
ICP (multi-target)

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice. in vivo imaging and ex vivo tracking.

Mouse
ICP
CTLA-4
PD-1
ICP (multi-target)

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice. in vivo imaging and ex vivo tracking.

Cells
MC38
ICP
Reporter
PD-L1

MC38-hPD-L1-hHER2-LZ

The  MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1  and human HER2.in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

CD39
Cells
MC38
Reporter
ICP

MC38-hCD39-LZ

The  MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form  infiltrated tumors in immunocompetent mice. in vivo imaging and ex vivo tracking.

CD20
Cells
ICP
Reporter
EL4

EL4-hCD20-LZ

The  EL4-hCD20-LZ clonal cell line expresses high levels of human CD20.in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

CD19
EL4
Cells
ICP
Reporter

EL4-hCD19-LZ

EL4-hCD19-LZ cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

CT26
Cells
ICP
EpCAM

CT26-hEpCAM-LZ

CT26-hEpCAM-LZ  clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo. in vivo imaging and ex vivo tracking.

CT26
Cells
ICP
CD39

CT26-hCD39-LZ

The CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo. in vivo imaging and ex vivo tracking.

ICP
PD-L1
Knockout
Cells
CT26

CT26-Pd-l1-ko

The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

PD-L1
Cells
Knockout
ICP

MC38-Pd-l1-ko

The Pd-l1 Knockout colon adenocarcinoma MC38 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

PD-L1
Cells
ICP

CT26-hPD-L1

The humanized PD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Mouse
PD-1
ICP
ICP (single-target)

hPD-1

The hPD-1 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 in fully immunocompetent mice. in vivo imaging and ex vivo tracking.

ICP
Cells
PD-L1
CD47
Reporter

MC38-hPD-L1-hCD47-LZ

The MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Humanized MC38-hPD-L1-LZ reporter tumor cell line

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.